COVID-19 infection triggers reactivation of dormant viruses already present in the human body, according to research examining viral coinfections in long COVID patients. The reactivated viruses include Epstein-Barr virus, cytomegalovirus, and several herpes viruses that typically remain latent in infected individuals.
Researchers discovered that one poorly characterized viral family showed strong association with long COVID and persistent disability. This connection offers a new direction for understanding why some COVID-19 survivors experience prolonged symptoms and reduced functional capacity months after initial infection.
The finding builds on growing evidence that long COVID involves multiple biological mechanisms beyond the initial viral infection. Previous studies have linked long COVID to persistent inflammation, autoimmune responses, and microclot formation. The discovery of dormant virus reactivation adds another layer to the condition's complexity.
Dormant herpesviruses occupy specialized cells throughout the body and remain controlled by immune surveillance in healthy individuals. COVID-19 infection can suppress or dysregulate this immune control, allowing previously latent viruses to replicate and cause renewed viral activity.
The specific poorly understood viral family implicated in long COVID represents a research opportunity. Identifying which viruses drive persistent symptoms could lead to targeted antiviral treatments or immunomodulatory therapies. Researchers may need to develop diagnostics to detect these reactivated viruses in long COVID patients.
This work connects to broader questions about post-viral syndromes. Other infections like Epstein-Barr and Lyme disease also trigger prolonged symptoms in some patients. Understanding whether viral reactivation plays a common role across these conditions could reshape treatment approaches.
The research remains preliminary regarding causation. Viral reactivation may contribute directly to long COVID symptoms, trigger immune dysregulation that causes symptoms, or represent a marker of more severe initial infection. Clinical trials would be needed to